A new study published in *Advances in Therapy* reveals that daridorexant, a sleep medication, may alleviate both insomnia and nocturia symptoms in older adults. The research, led by Dario Arnaldi from the University of Genoa and Donald Bliwise from Emory University, analyzed open-ended patient feedback from a randomized, placebo-controlled crossover trial involving 60 participants aged 55 and above, all of whom experienced chronic insomnia and nocturia.
Read More
The clinical trial, registered under NCT05597020, included adults who reported insomnia symptoms for over three months with insomnia severity scores of 13 or higher and at least three nocturnal voids per night. Participants were randomly assigned to receive either 50 mg of daridorexant or a placebo for four weeks before switching treatments after a 14 to 21-day washout period. This crossover design allowed each participant to serve as their own control, enhancing the reliability of comparisons between the two treatments.
What differentiates this study is its focus on the qualitative aspects of patient experiences. In addition to standardized assessments, patients provided detailed open-ended responses before and after each treatment period regarding how their insomnia and nocturia impacted their daily lives. The analysis categorized responses to distinguish between changes experienced while on daridorexant versus placebo, maintaining blinded coding throughout the process.
The initial findings highlighted the severity of the issues participants faced: 68 percent described sleep disturbances, and 37 percent reported nocturia. A significant 83 percent of respondents noted detrimental impacts on their daily lives, with fatigue and emotional distress cited frequently.
After four weeks, 87 percent of patients taking daridorexant reported improved sleep, compared to only 50 percent in the placebo group. Likewise, 79 percent of those on daridorexant noted an improvement in nocturia, while only 32 percent on placebo reported similar outcomes. The quantitative results corroborated these findings, indicating a mean increase in total sleep time of approximately 21 minutes and a reduction in nocturnal voids by an average of 1.5 episodes per night among the daridorexant group.
Enhanced quality of life was also observed, with 73.7 percent of daridorexant patients reporting positive changes compared to 46.7 percent on placebo. Notable improvements were seen in physical functioning and cognitive abilities, further emphasizing the broader impacts of treating insomnia and nocturia.
The study proposes two hypotheses for why a sleep medication would help reduce nighttime urination. One theory suggests that increased sleep duration limits opportunities for patients to notice a full bladder. The second posits a neurobiological connection, as the orexin system, known to regulate wakefulness, may also influence bladder function.
Despite some limitations, including recall bias and potential placebo effects, the study’s authors assert that their findings highlight significant issues faced by older adults suffering from insomnia and nocturia. They advocate for more qualitative research in sleep medicine to capture the nuanced patient experiences often overlooked in quantitative assessments. This study serves as a model for integrating patient voices into clinical research.